GH — Guardant Health, Inc.

Summary of Guardant Health Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $281.3 million, up 39% year-over-year.
• Full Year Revenue: $982.0 million, a 33% increase.
• Oncology Revenue: $189.9 million in Q4, up 30% year-over-year, with approximately 79,000 tests conducted (38% volume growth).
• Biopharma and Data Revenue: $54.0 million in Q4, up 9%.
• Screening Revenue: $35.1 million from approximately 38,000 Shield tests.
• Non-GAAP Gross Margin: Improved to 66% in Q4, up from 63% year-over-year.
• Adjusted EBITDA Loss: Improved to $64.9 million in Q4 from $78.4 million in the prior year.
• Free Cash Flow Burn: $233 million for the year, with a target of $185 million to $195 million for 2026.

2. Strategic Updates and Business Highlights

• Product Innovations: Launched several new applications for Guardant360 and expanded Shield for multi-cancer detection.
• Medicare Coverage: Gained coverage for colorectal cancer surveillance with Reveal, enhancing adoption.
• Commercial Expansion: Increased sales force to approximately 300 reps and established partnerships with Quest Diagnostics and PathGroup to broaden market reach.
• Acquisition: Acquired MetaSight Diagnostics for $59 million, aimed at enhancing the product portfolio and accelerating multi-disease detection capabilities.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $1.25 billion and $1.28 billion, reflecting 27% to 30% growth.
• Oncology Revenue Growth: Forecasted at 25% to 27%, driven by strong demand for Guardant360 and Reveal.
• Screening Revenue Guidance: Anticipated between $162 million and $174 million, with expected tests between 210,000 to 225,000.
• Gross Margin Expectations: Projected non-GAAP gross margin in the range of 64% to 65% for 2026.

4. Bad News, Challenges, or Points of Concern

• Declining ASPs for Shield: Expected decrease in average selling prices due to a mix shift towards non-Medicare patients.
• Seasonality Impact: Anticipated seasonal decline in Shield volumes in Q1 2026, which could affect early-year performance.
• Regulatory Risks: Uncertainty surrounding the timing and impact of FDA approvals for new products and reimbursement pathways.
• Competitive Landscape: Challenges from competitors in the multi-cancer detection space, particularly regarding clinical performance and regulatory approvals.

5. Notable Q&A Insights

• Reveal Monitoring: Management expressed optimism about the potential for Reveal in therapy monitoring, which could drive future growth.
• Sales Force Strategy: Plans to continue investing in the sales force for both oncology and screening, with a focus on building out commercial infrastructure.
• MCED Legislation: While recent legislation is seen as positive for the field, it is not expected to have a near-term impact on revenue.
• Guardant360 and Tissue Testing: Anticipated FDA approval could allow concurrent ordering of blood and tissue tests, potentially boosting demand.

Overall, Guardant Health reported strong financial growth and strategic advancements in Q4 2025, with a positive outlook for 2026, despite some challenges related to pricing and market competition.